Raymond James Maintains "Outperform" Rating for Johnson & Johnson (NYSE:JNJ)

Core Viewpoint - Raymond James maintains an "Outperform" rating for Johnson & Johnson and raises its price target from $174 to $209, reflecting confidence in the company's future performance [1][5] Group 1: Financial Performance - Johnson & Johnson recently increased its 2025 sales forecast after a strong quarterly earnings report that exceeded Wall Street's expectations [2][5] - The company's stock is currently trading at $190.85, with a slight decrease of 0.05, reflecting a percentage change of approximately -0.03% [3] - Over the past year, JNJ has reached a high of $194.40 and a low of $140.68, showcasing its resilience in the market [3] Group 2: Market Position - Johnson & Johnson's market capitalization stands at approximately $459.63 billion, indicating its significant presence in the healthcare industry [4] - The stock has a trading volume of 11.27 million shares, reflecting investor interest and confidence in the company's future performance [4] Group 3: Strategic Moves - The company's strategic decision to spin off its orthopedics business into a standalone entity is expected to contribute to its growth prospects [2][5]